Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma.
O6-methylguanine-DNA methyltransferase
intranasal
isocitrate dehydrogenase 1
perillyl alcohol
recurrent glioblastoma
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Better treatments for glioblastoma (GBM) patients, in particular in the recurrent setting, are urgently needed. Clinical trials performed in Brazil indicated that intranasal delivery of perillyl alcohol (POH) might be effective in this patient group. NEO100, a highly purified version of POH, was current good manufacturing practice (cGMP) manufactured to evaluate the safety and efficacy of this novel approach in a Phase I/IIa clinical trial in the United States. A total of 12 patients with recurrent GBM were enrolled into Phase I of this trial. NEO100 was administered by intranasal delivery using a nebulizer and nasal mask. Dosing was 4 times a day, every day. Four cohorts of 3 patients received the following dosages: 96 mg/dose (384 mg/day), 144 mg/dose (576 mg/day), 192 mg/dose (768 mg/day), and 288 mg/dose (1152 mg/day). Completion of 28 days of treatment was recorded as 1 cycle. Adverse events were documented, and radiographic response Intranasal NEO100 was well tolerated at all dose levels and no severe adverse events were reported. PFS-6 was 33%, OS-12 was 55%, and median OS was 15 months. Four patients (33%), all of them with isocitrate dehydrogenase 1 (IDH1)-mutant tumors, survived >24 months. Intranasal glioma therapy with NEO100 was well tolerated. It correlated with improved survival when compared to historical controls, pointing to the possibility that this novel intranasal approach could become useful for the treatment of recurrent GBM.
Sections du résumé
BACKGROUND
BACKGROUND
Better treatments for glioblastoma (GBM) patients, in particular in the recurrent setting, are urgently needed. Clinical trials performed in Brazil indicated that intranasal delivery of perillyl alcohol (POH) might be effective in this patient group. NEO100, a highly purified version of POH, was current good manufacturing practice (cGMP) manufactured to evaluate the safety and efficacy of this novel approach in a Phase I/IIa clinical trial in the United States.
METHODS
METHODS
A total of 12 patients with recurrent GBM were enrolled into Phase I of this trial. NEO100 was administered by intranasal delivery using a nebulizer and nasal mask. Dosing was 4 times a day, every day. Four cohorts of 3 patients received the following dosages: 96 mg/dose (384 mg/day), 144 mg/dose (576 mg/day), 192 mg/dose (768 mg/day), and 288 mg/dose (1152 mg/day). Completion of 28 days of treatment was recorded as 1 cycle. Adverse events were documented, and radiographic response
RESULTS
RESULTS
Intranasal NEO100 was well tolerated at all dose levels and no severe adverse events were reported. PFS-6 was 33%, OS-12 was 55%, and median OS was 15 months. Four patients (33%), all of them with isocitrate dehydrogenase 1 (IDH1)-mutant tumors, survived >24 months.
CONCLUSION
CONCLUSIONS
Intranasal glioma therapy with NEO100 was well tolerated. It correlated with improved survival when compared to historical controls, pointing to the possibility that this novel intranasal approach could become useful for the treatment of recurrent GBM.
Identifiants
pubmed: 33604574
doi: 10.1093/noajnl/vdab005
pii: vdab005
pmc: PMC7879254
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab005Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
J Neurooncol. 2016 Aug;129(1):147-54
pubmed: 27270908
J Oncol Pharm Pract. 2018 Jan;24(1):33-36
pubmed: 27903792
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Lancet Oncol. 2014 Aug;15(9):943-53
pubmed: 25035291
Mol Cancer Ther. 2012 Nov;11(11):2462-72
pubmed: 22933703
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
Gynecol Oncol. 2002 Jun;85(3):464-8
pubmed: 12051875
J Control Release. 2012 Jul 20;161(2):254-63
pubmed: 22300620
Clin Cancer Res. 2000 Feb;6(2):390-6
pubmed: 10690515
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Cancer Res Clin Oncol. 2011 Feb;137(2):287-93
pubmed: 20401670
J Clin Oncol. 1999 Aug;17(8):2572-8
pubmed: 10561324
J Neurooncol. 2016 Feb;126(3):567-75
pubmed: 26614518
Neuropharmacology. 2018 Jul 1;136(Pt B):196-201
pubmed: 29180222
Curr Drug Deliv. 2012 Nov;9(6):566-82
pubmed: 22788696
Neurology. 2008 Feb 5;70(6):440-8
pubmed: 17942819
Jpn J Clin Oncol. 2021 Jan 1;51(1):45-53
pubmed: 32888020
J Clin Oncol. 2013 Sep 10;31(26):3212-8
pubmed: 23940216
Int J Gastrointest Cancer. 2002;32(2-3):125-8
pubmed: 12794248
Curr Probl Dermatol. 2011;40:20-35
pubmed: 21325837
Am J Cancer Res. 2015 Apr 15;5(5):1580-93
pubmed: 26175929
J Neurooncol. 2014 Feb;116(3):437-46
pubmed: 24398618
Sci Transl Med. 2016 Jun 1;8(341):341ra75
pubmed: 27252174
CNS Oncol. 2015;4(3):157-69
pubmed: 25906439
Neuro Oncol. 2015 Nov;17(11):1504-13
pubmed: 26130744
Carcinogenesis. 2019 Nov 25;40(11):1299-1307
pubmed: 31504231
J Pharm Sci. 2010 Apr;99(4):1654-73
pubmed: 19877171
Anticancer Res. 2013 Dec;33(12):5625-31
pubmed: 24324108
Neuro Oncol. 2016 Sep;18(9):1304-12
pubmed: 26951379
Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7
pubmed: 18295834
Invest New Drugs. 2003 Aug;21(3):367-72
pubmed: 14578686
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223
Adv Drug Deliv Rev. 2005 Nov 3;57(11):1640-65
pubmed: 16182408
Crit Rev Oncol Hematol. 2017 Mar;111:60-65
pubmed: 28259296
Cancer Lett. 1995 May 8;91(2):169-75
pubmed: 7767906